FNY Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

FNY Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49K	Buy	+100	New	+$44.3K	0.02%	422
2021 Q3	–	Sell	-50	Closed	-$10K	–	935
2021 Q2	$10K	Buy	50 +10	+25%	+$2.09K	﹤0.01%	578
2021 Q1	$8K	Buy	+40	New	+$8.79K	﹤0.01%	594
2019 Q3	–	Sell	-70	Closed	-$12K	–	1191
2019 Q2	$12K	Buy	+70	New	+$12.2K	﹤0.01%	594
2018 Q4	–	Sell	-854	Closed	-$164K	–	1052
2018 Q3	$164K	Sell	854 -146	-15%	-$26K	0.04%	207
2018 Q2	$169K	Buy	+1,000	New	+$155K	0.07%	172

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

FNY Investment Advisers's VRTX Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 100 shares worth $49K. The stake represents 0.02% of the portfolio and ranks #422 among its holdings. This is a return to the name: FNY Investment Advisers previously reported a position in VRTX as recently as Q2 2021.

FNY Investment Advisers first reported a position in VRTX in Q2 2018 and has held it in 6 quarters since. The position peaked at $169K in Q2 2018. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

FNY Investment Advisers held 100 shares of Vertex Pharmaceuticals worth $49K as of Q2 2026.
Vertex Pharmaceuticals was a new FNY Investment Advisers position in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of FNY Investment Advisers's portfolio in Q2 2026, its #422 holding.
FNY Investment Advisers first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
FNY Investment Advisers's Vertex Pharmaceuticals position peaked at $169K in Q2 2018.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.